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Abstract
Purpose: To monitor the outcomes for intermediate-risk prostate cancer patients treated with biologically effective 
dose (BED) ≥ 200 Gy radiotherapy using low-dose-rate (LDR) brachytherapy.
Material and methods: Between 2005 and 2016, a total of 397 patients with intermediate-risk prostate cancer were 
treated by LDR-based radiotherapy with a BED ≥ 200 Gy. Treatments consisted of LDR brachytherapy alone (177 cases) 
or LDR and external beam radiotherapy (EBRT) (220 cases). Short-term androgen deprivation therapy (ADT) was used 
in 186 patients (46.9%). The median follow-up period was 72 months (range 29-165 months). Dosimetric parameters 
and BED were studied in each case. The numbers of intermediate-risk features were: 163 patients with 1 intermedi-
ate-risk feature (41%), 169 patients with 2 intermediate-risk features (43%), and 65 patients with 3 intermediate-risk 
features (16%). A total of 145 cases were diagnosed as having primary Gleason pattern 4: Gleason score 4 + 3 (36.5%). 
Results: Three patients developed biochemical failure, thus providing a 7-year actual biochemical failure-free sur-
vival (BFFS) rate of 99.1%. Biochemical failure was observed exclusively in cases with distant metastasis: two cases 
with lymph node metastasis and one case with bone metastasis, thus yielding a 7-year freedom from clinical failure 
(FFCF) rate of 99.1%. We observed eight deaths, but there was no death from prostate cancer, thus yielding a 7-year 
cause-specific survival (CSS) rate of 100%, and an overall survival (OS) rate of 98.4%.
Conclusions: This study highlights excellent outcomes for intermediate-risk prostate cancer patients, including un-
favorable intermediate-risk cases, treated with BED ≥ 200 Gy radiotherapy using LDR brachytherapy. LDR alone with 
a BED of 200 Gy may be an optimal treatment for both favorable and unfavorable intermediate-risk prostate cancer 
patients, although a longer follow-up is mandatory to confirm the present findings.
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Purpose
Intermediate-risk prostate cancer patients represent 
the largest of the risk groups and comprise a heteroge-
neous population of patients with variable prognoses [1]. 
According to National Comprehensive Cancer Network 
Criteria (http://www.nccn.org/) intermediate-risk pros-
tate cancer patients were defined as intermediate-risk if 
they fulfilled at least one of the following criteria: pros-
tate-specific antigen (PSA) level 10-20 ng/ml, and/or 
Gleason score = 7, and/or clinical stage T2b or T2c.
Patients within the intermediate-risk category experi-
enced a significant biochemical recurrence (at least 30%) 
following treatment with radical prostatectomy or exter-
nal beam radiation therapy (EBRT) [2,3]. These reports 
also described heterogeneity of both biochemical and 
clinical recurrence rates in the intermediate-risk prostate 
cancer patients. Based on this heterogeneity of interme-
diate-risk prostate cancer, a new classification subdivid-
ing patients with intermediate-risk prostate cancer into 
“favorable” and “unfavorable” subgroups has been pro-
posed:
•  favorable intermediate-risk (FIR): one IR factor with 
Gleason score 3 + 4,
•  unfavorable intermediate-risk (UIR): Gleason 4 + 3 = 7 
or > 1 intermediate-risk factors (cT2b, cT2c, PSA 10-20, 
Gleason 3 + 4 = 7).
The probability for biochemical recurrence in UIR pa-
tients is significantly higher than that in FIR patients fol-
lowing treatments with radical prostatectomy or EBRT of 
81 Gy [4,5]. We have previously obtained excellent results 
in terms of biochemical failure-free survival (BFFS) and lo-
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cal control in high-risk and very high-risk cancer, includ-
ing cases with nodal metastasis, by high-dose (biologically 
effective dose – BED > 220 Gy) radiotherapy by low-dose-
rate (LDR) brachytherapy in combination with EBRT: the 
data showed a 5-year actual BFFS rate of 95.2% [6].
In our present study on the efficacy and toxicity of 
LDR brachytherapy-based radiotherapy in our institu-
tion, we report clinical outcomes for intermediate-risk 
prostate cancer patients, including both favorable and un-
favorable groups, treated with LDR brachytherapy-based 
radiotherapy with a BED ≥ 200 Gy.
Material and methods
Patients
This retrospective and observational study was con-
ducted in accordance with the Helsinki Declaration. This 
study has been approved and monitored by our institu-
tional ethics committee (R-2019-120).
From 2005 to 2016, a total of 397 patients with inter-
mediate-risk prostate cancer were treated by LDR-based 
radiotherapy with a BED > 200 Gy. 
The patients were classified according to the National 
Comprehensive Cancer Network Criteria (http://www.
nccn.org/): briefly, patients were defined as intermedi-
ate-risk if they fulfilled at least one of the following crite-
ria: prostate-specific antigen (PSA) 10-20 ng/ml, and/or 
Gleason score = 7, and/or clinical stage T2b or T2c.
The intermediate-risk patients in the present study in-
cluded any type of intermediate-risk patient: both favor-
able and unfavorable intermediate-risk patients.
Staging
Clinical T stage was determined by a combination of 
magnetic resonance imaging (MRI) and digital examina-
tion. All patients had bone scans and computed tomogra-
phy (CT) of the pelvis to check for the presence of bone 
metastasis and lymph node metastasis.
Clinical characteristics
The clinical characteristics of the patients (PSA, Glea-
son score clinical T stage) are shown in Table 1. The dis-
tribution of the number of intermediate-risk factors is 
shown in Table 2. A total of 145 cases were diagnosed as 
having primary Gleason pattern 4: Gleason score 4 + 3 
(36.5%).
Treatment
A total of 397 patients with intermediate-risk prostate 
cancer were treated by LDR-based radiotherapy with 
a BED ≥ 200 Gy. Treatment consisted of LDR brachyther-
apy alone (177 cases) or LDR and EBRT (220 cases). Short-
term (3-6 months) androgen deprivation therapy (ADT) 
was used in 186 patients (46.9%).
Androgen deprivation therapy consisted of gonado-
tropin-releasing hormone agonist injection and anti-an-
drogen. LDR brachytherapy implantation in the prostate 
was conducted with 125I seeds using real-time ultrasound 
guided technique [7]. Radioactive seeds were deposit-
ed into the prostate using a Mick applicator (Mick Ra-
dio-Nuclear Instruments, Ind., Mount Vernon, NY). 
The prescription dose of seed implantation was set at 
144 Gy for LDR monotherapy and 110 Gy for LDR com-
bined with EBRT. In order to achieve high dose seed im-
plantation, we set D90 at 190 Gy for LDR monotherapy and 
D90 at 135-140 Gy for LDR and EBRT combination therapy 
upon seed implantation. To achieve this goal, we intention-
ally made a high dose cloud (dose areas of 240 Gy for LDR 
monotherapy and 160 Gy for LDR and EBRT combination 
therapy) intentionally along the periphery (bilateral wall 
to anterior wall of the prostate) away from the urethra and 
rectum: the detailed report on this high dose seed implan-
tation technique is now under preparation separately. For 
this method, we routinely used seed activity at 11.0 MBq. 
In both LDR monotherapy and LDR combined with 
EBRT, the radiation dose was set to achieve a total BED of 
200 Gy: Post-implant dosimetry with CT and MRI guid-
ance was carried out one month after seed implantation.
Table 1. Patient and disease characteristics of 
the 397 intermediate-risk cases are shown
Variable n = 397 (%)
Age (years), median (range) 66.2 (45-80)
PSA at diagnosis (ng/ml)
< 10 248 (62.5%)
10-20 149 (37.5%)




3 + 4 207 (52.1)








Table 2. Composition of intermediate-risk featu-
res in the 397 cases is shown
Number of intermediate-risk 
features




Journal of Contemporary Brachytherapy (2020/volume 12/number 1)
Keisei Okamoto, Kahori Okuyama, Naoaki Kohno, et al.8
For LDR monotherapy, D90 of the prostate was set 
over 190 Gy so that the post-implant BED would be high-
er than 200 Gy.
For combination therapy with LDR and EBRT, sup-
plemental EBRT was delivered four to eight weeks after 
seed implantation. EBRT consisted of a median dose of 
45 Gy given in 1.8 Gy fractions via a three-dimensional 
conformal technique. 
In each case, the BED was calculated from the pros-
tate D90 of the LDR and EBRT dose using the formula de-
scribed previously [8]: the EBRT dose was determined so 
that the total BED would be higher than 200 Gy as long as 
UD30 and R100 were tolerable. EBRT fields included pros-
tate and seminal vesicles only with a margin. Clinical tar-
get volume (CTV) was designed as the entire prostate and 
seminal vesicle. Planning target volume (PTV) included 
CTV-block with a 15 mm margin except at the prostato-
rectal interface, where a 7-10 mm was used.
Trend change of treatment modalities
To see our treatment trends during our 15-year LDR 
experience, we examined the modality ratio among LDR 
monotherapy and combination therapy with LDR and 
EBRT for 3 years.
Follow-up and statistical analysis
Scheduled follow-ups were done by PSA blood test 
and physical examination every three months for the first 
two years, followed by every six months thereafter. The 
follow-up duration was calculated from the time of the 
LDR for LDR monotherapy, and from the end of the sup-
plemental EBRT for combination therapy. These patients 
had a minimum follow-up time of two years: the median 
follow-up was 72 months (range 29-165 months).
Actuarial survival curves were calculated by the Ka-
plan-Meier method to determine BFFS, freedom from 
clinical failure (FFCF) survival, cause-specific surviv-
al (CSS) and overall survival (OS). Biochemical failure 
was defined according to the Phoenix Definition [8]. The 
criterion for biochemical failure with subsequent PSA 
decrease to < 0.5 ng/ml without intervention was cate-
gorized as a benign bounce and was excluded from the 
biochemical failure group. Upon a true biochemical fail-
ure, we performed CT, MRI, bone scan and rectal digi-
tal examination to see whether biochemical failure was 
caused by distant metastasis or local failure.
Biochemical failure-free survival was calculated for all 
living patients and reflected biochemical failures. FFCF 
survival rate was calculated for all living patients and re-
flected clinical failure events (local, regional and distant 
failure). CSS reflected prostate cancer-specific death. OS 
reflected all deaths, cancer related or unrelated.
Toxicity
Acute toxicity was defined when symptoms devel-
oped within the first year after seed implantation. Late 
toxicity was defined when any kind of symptom de-
veloped after one year or when any symptom occurred 
within the first year and persisted for more than one year. 
Toxicity was recorded by the Common Terminology Cri-
teria for Adverse Events version 4.0.
Results
Trend change in treatment modalities
The trend changes of our treatment modalities for ev-
ery three years of our 15-year LDR experience are shown 
in Figure 1.
During the early period, we used combination thera-
py with LDR and EBRT with or without ADT for interme-
diate-risk patients. The reason for using LDR and EBRT 
combination therapy was to deliver high BED > 200 Gy 
for intermediate-risk patients. In those days, we did not 
have sufficient technique to deliver high BED of 200 Gy 
without using EBRT. During the early period, we also 
used ADT particularly for UIR cases or cases with pros-
tate volume ≥ 40 ml. In 2012, we stopped using ADT in 
any type of intermediate-risk patients.
Our current treatment policy is that BED is the most 
crucial factor for local control of intermediate-risk pros-
tate cancer. Therefore, we do not use EBRT or ADT in 
most cases of intermediate-risk prostate cancer including 
UIR cases at present.
Dosimetric parameters and BED
Dosimetric parameters of LDR monotherapy (N = 177) 
based on the data at one month after LDR are shown in 
Table 3.
The average D90 and BED of LDR monotherapy were 
192.5 Gy and 203 Gy, respectively.
Dosimetric parameters of combination therapy with 
LDR and EBRT (N = 220) based on the data at one month 
after LDR are shown in Table 4.
The average D90 of LDR and total BED of the combi-
nation therapy were 133.9 Gy and 220.3 Gy, respectively.
Efficacy of the treatment
Three patients developed biochemical failure, thus 
providing a 7-year actual biochemical failure-free surviv-
al (BFFS) rate of 99.1% (Figure 2). Biochemical failure was 
observed exclusively in cases with distant metastasis: two 
cases with lymph node metastasis and one case with bone 
 2005-2007 2008-2010 2011-2013 2014-2016
Fig. 1. Trend change of treatment modalities in our 15-year 
LDR experience. Modality ratio among LDR monotherapy 
(white bar) and combination therapy with LDR and EBRT 
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metastasis, thus yielding a 7-year freedom from clinical 
failure (FFCF) rate of 99.1% (Figure 2). We observed eight 
deaths, but there was no death from prostate cancer, thus 
yielding a 7-year cause-specific survival (CSS) rate of 
100%, and an OS rate of 98.4% (Figure 2).
The number of intermediate-risk features of the 
patients who developed biochemical failure
We analyzed the number of intermediate-risk features 
of the three patients who developed biochemical failure. 
Case 1 with two intermediate-risk features: clinical fail-
ure with bone metastasis. Pretreatment PSA = 11.0 ng/ml, 
T2c, Gleason score = 3 + 3. Case 2 with one intermedi-
ate-risk feature: clinical failure with lymph-node metas-
tasis. PSA = 7.8 ng/ml, T2b, Gleason score = 3 + 3. Case 3 
with three intermediate-risk features: clinical failure with 
lymph-node metastasis. PSA = 11.2 ng/ml, T2b, Gleason 
score = 3 + 4. Thus, occult metastasis existed regardless of 
the number of intermediate-risk patients.
Toxicity
Acute grade 2 genitourinary (GU) and gastrointestinal 
(GI) toxicity was experienced by 44 patients (11.1%) and 
two patients (0.5%), respectively. Late grade 2 GU and GI 
toxicity was experienced by 48 patients (12.0%) and five 
patients (1.3%), respectively. Grade 3 GU toxicity was not 
observed.
Grade 3 GI toxicity was observed in one patient 
(0.3%): R100 of this case at one month after seed implan-
tation was 1.8 cc. Therefore, we reduced the EBRT dose 
down to 30.6 Gy. However, the patient experienced grade 
3 rectal bleeding and received a blood transfusion. The 
patient recovered well without recurrent rectal bleeding 
after that.
This patient was an early-experience case (case num-
ber 20 of the 397 cases) treated by combination therapy 
with LDR and EBRT. The patient is alive and has since 
been free from rectal bleeding.
None of the patients experienced urethral stricture, 
TUR-P (transurethral resection of prostate), or recto-ure-
thral fistula. 
Discussion
In the present study, we demonstrated that a series 
of intermediate-risk prostate cancer patients in our in-
stitution obtained excellent recurrence-free survival ei-
ther by LDR monotherapy or by combination therapy 
and LDR.
Notably, our intermediate-risk patients included 
a significant number of UIR patients. Overall, only three 
patients (0.8%) experienced biochemical failure (BFFS 
rate of 99.1% at seven years). Biochemical failure was 
observed exclusively in cases with distant metastasis 
(lymph node metastasis in two cases and bone metastasis 
in one case) (FFCF rate of 99.1% at seven years).
Radical prostatectomy is one of the standard treat-
ment modalities for intermediate-risk prostate cancer. 
A group at Johns Hopkins University reported on BFFS 
in a cohort of 4,164 intermediate-risk patients. The results 
showed that 5-year BFFS differed significantly between 
FIR patients and UIR patients: For patients with one in-
termediate-risk factor, the 5-year BFFS was 83.0%, com-
pared with 64.3% for men with two risk factors and 45.9% 
for those with three risk factors [4]. Similar differences in 
BFFS between FIR patients and UIR patients have been 
reported for EBRT of 81 Gy [5]. In their report, the es-
timated 8-year BFFS rates are 86.1% and 71.1% in FIR 
patients and UIR patients, respectively. The estimated 
8-year local failure rates are 9.1% and 12.4% for FIR pa-
tients and UIR patients, respectively. The 8-year prostate 
Table 3. Dosimetric parameters of seed implan-
tation at one month and calculated BED in the 
177 cases treated by LDR monotherapy is shown
Number of cases treated by seed LDR 
monotherapy




Prostate volume (cc) 33.7 (23.5-45.0)
Prostate D90 (Gy) 192.5 (155.3-223.8)
V100 (%) 98.9 (93.9-100)
UD30 (Gy) 212.65 (155.7-268.9)
R100 (cc) 0.49 (0-2.17)
BED (Gy) 203.58 (163.8-241.4)
V100 – The percentage prostate volume receiving 100% of the prescribed mini-
mal peripheral dose, UD30 – minimal dose (Gy) received by 30% of the urethra, 
R100 – rectal volume (ml) receiving 100% of the prescribed dose
Table 4. Dosimetric parameters of seed implan-
tation at one month and calculated total BED 
with LDR and EBRT in the 220 cases treated by 
combination therapy with LDR and EBRT are 
shown
Number of cases treated by combina-





Prostate volume (cc) 21.3 (10.4-57.5)
Prostate D90 (Gy) 133.9 (100.0-163.0)
V100 (%) 97.3 (88-100)
UD30 (Gy) 165.0 (107.6-230.0)
R100 (cc) 0.34 (0-2.08)
Total BED of combination therapy (Gy) 220.7 (189.0-226.2)
V100 – The percentage prostate volume receiving 100% of the prescribed mini-
mal peripheral dose, UD30 – minimal dose (Gy) received by 30% of the urethra, 
R100 – rectal volume (ml) receiving 100% of the prescribed dose
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cancer-specific mortality rates are 2.0% and 4.2% in FIR 
patients and UIR patients, respectively.
Grimm et al. conducted a large-scale comprehensive 
review of the literature comparing risk-stratified patients 
by treatment option and with long-term follow-up [9]. The 
outcome for intermediate-risk patients varied significant-
ly among the treatment options. At 8 years, the estimat-
ed median BFFS rates for intermediate-risk patients were 
90%, 85%, 70% and 70% among combination therapy with 
LDR and EBRT, LDR monotherapy, radical prostatecto-
my, and EBRT. In each treatment modality, BFFS differed 
substantially among the reports or institutions. There may 
be several reasons for those differences: 1) technical rea-













































Fig. 2. Kaplan-Meier BFFS, FFCF, CSS and OS. A – Kaplan-Meier BFFS: BFFS rate is 99.1% at 7 years. B – Kaplan-Meier FFCF: 
FFCF rate is 99.1% at 7 years. C – Kaplan-Meier CSS: CSS rate is 100% at 7 years. D – Kaplan-Meier OS: OS rate is 98.4%.
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Use of prostate brachytherapy provides the advan-
tage of safely delivering a high biologically effective dose 
(BED) to the prostate [8,10,11].
It has been debated whether there is a need for supple-
mental EBRT when applying LDR-based radiotherapy in 
intermediate-risk cancer patients [12,13]. In those debates, 
there is a clear agreement that dose escalation is a key to 
improving outcomes for intermediate-risk patients, in-
cluding UIR patients [12,13]. 
The advantage of combination therapy with LDR 
brachytherapy and EBRT has been recently confirmed by 
the ASCENDE randomized trial [14].
Indeed, we have previously shown that high-dose 
(BED > 220 Gy) radiotherapy by LDR in combination 
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with EBRT leads to excellent BFFS and local control in 
high-risk and very high-risk cancer [6]. 
A crucial question remains how high BED is re-
quired for intermediate-risk patients including UIR cas-
es. Based on the previous review [12], we suggest that 
a BED of 200 Gy is high enough for intermediate-risk 
patients, including UIR cases.
The present study on intermediate-risk cancer includ-
ed a significant number of UIR patients. We did not con-
duct a statistical analysis on the BFFS rate among FIR and 
UIR patients in this study because biochemical failure 
was observed in only three cases. Therefore, the present 
study may at least prove the efficacy of outcome by our 
LDR-based radiotherapy for intermediate-risk prostate 
cancer patients, including UIR cases.
Furthermore, our series of patients did not experience 
any local recurrence within the present follow-up period, 
although much longer follow-up is necessary to exclude 
this possibility. 
The present data may suggest that a BED of 200 Gy is 
high enough for eradicating both FIR and UIR prostate 
cancer. Our treatment trend change in intermediate-risk 
prostate cancer patients has moved forward to LDR 
monotherapy without ADT: This trend became evident 
in the last five years. 
The background for this trend change is based on the 
technical advances in delivering a BED of 200 Gy safely 
by LDR monotherapy and accurate seed implantation for 
large volume prostate regardless of pubic arch interfer-
ence (unpublished data). 
Our study limitations included: 1) the short period 
of follow-up; 2) the retrospective character of this study. 
Even considering these shortcomings, this study suggests 
that LDR-based radiotherapy with a BED ≥ 200 Gy may 
result in good BFFS in intermediate-risk prostate cancer 
patients, including UIR. 
Conclusions
This study shows an excellent outcome for intermedi-
ate-risk prostate cancer patients treated with BED ≥ 200 
Gy radiotherapy using LDR brachytherapy. LDR alone 
achieving a BED > 200 Gy may be considered an opti-
mal treatment in both favorable and unfavorable inter-
mediate-risk prostate cancer patients, although a longer 
follow-up is mandatory.
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